Company Overview:
TG Therapeutics
TGTX is a biotech leader focused on novel cancer and autoimmune treatments, gaining momentum as an IBD Leaderboard and IBD 50 Top 10 Growth Stock.
Key Catalysts:
Regulatory Approvals & Expansion 🌍
BRIUMVI secured approvals in Europe & the UK, unlocking new revenue streams in key markets.
Strong Profitability & Growth 💰
88.3% gross margin ensures sustainable reinvestment into R&D and future pipeline advancements.
High-Growth Stock Recognition 📊
Technical strength is validated by its inclusion in top-performing stock lists, signaling strong investor confidence.
Investment Outlook:
Bullish Case: We are bullish on TGTX above $34.00-$35.00, driven by global expansion, financial strength, and biotech leadership.
Upside Potential: Our price target is $55.00-$56.00, supported by continued innovation and market penetration.
🔥 TG Therapeutics – Pioneering the Future of Cancer Treatment. #TGTX #Biotech #GrowthStocks
TG Therapeutics
TGTX is a biotech leader focused on novel cancer and autoimmune treatments, gaining momentum as an IBD Leaderboard and IBD 50 Top 10 Growth Stock.Key Catalysts:
Regulatory Approvals & Expansion 🌍
BRIUMVI secured approvals in Europe & the UK, unlocking new revenue streams in key markets.
Strong Profitability & Growth 💰
88.3% gross margin ensures sustainable reinvestment into R&D and future pipeline advancements.
High-Growth Stock Recognition 📊
Technical strength is validated by its inclusion in top-performing stock lists, signaling strong investor confidence.
Investment Outlook:
Bullish Case: We are bullish on TGTX above $34.00-$35.00, driven by global expansion, financial strength, and biotech leadership.
Upside Potential: Our price target is $55.00-$56.00, supported by continued innovation and market penetration.
🔥 TG Therapeutics – Pioneering the Future of Cancer Treatment. #TGTX #Biotech #GrowthStocks
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.